Emerson Electric Co. (EMR) fair value analysis
S&P 500 · Updated 2026-10-19
EMR price how computed
Forward Fair Value verdict
OvervaluedEMR is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $161.83
- Sector
- Industrials
- 12-month range
- $123.30–$164.38
- Market cap
- $90.6B
- From 52-week high
- -1.6%
- Shares outstanding
- 560M
- Rank in Industrials by discount to fair value
- #74 of 106
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Emerson Electric Co. is an industrial technology company that designs and manufactures process management and climate technologies for customers across various industries. The company operates globally, serving markets in North America, Europe, Asia, and other regions around the world.
EMR currently ranks #74 of 106 Industrials stocks by discount to fair value. It has screened as Overvalued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $90.6B
- P/E (trailing)
- 26x
- Revenue (TTM)
- $18.6B
- Net margin
- 13.8%
- EPS (TTM)
- $6.33
- Gross margin
- 54.5%
- Debt / equity
- 0.68
- Revenue growth (3-yr avg)
- 6.4%
- Shares outstanding
- 560M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 68 · neutral
- 50-day average
- $156.41
- 200-day average
- $145.98
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $2.22 per share (4 payments)
- Yield on last price
- 1.37%
- Consecutive years of increases
- 18
- Last ex-dividend date
- 2026-08-14
- Last payment date
- 2026-09-10
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.8%)
2026-03 ▲ beat (+0.7%)
2025-12 ▲ beat (+3.5%)
2025-09 ▬ met (0.0%)
2025-06 ▲ beat (+0.7%)
2025-03 ▲ beat (+5.0%)
2024-12 ▲ beat (+7.8%)
2024-09 ▲ beat (+0.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 20 buy · 8 hold · 2 sell (30 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $174
- Target vs last price
- +7.5%
What our data shows for EMR
- Our model validated 17 trailing price-to-earnings windows for EMR, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $123.30–$164.38.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EMR
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent EMR news
TickrTrends' derived news-sentiment signal for EMR is currently leaning positive, computed from recent coverage.
- Emerson Electric Co. (EMR) is Attracting Investor Attention: Here is What You Should Know (zacks.com, 2026-10-20)
TickrTrends take: Emerson Electric operates in the Industrials sector where valuation multiples vary significantly based on growth prospects and capital efficiency. TickrTrends currently assigns an Overvalued verdict to EMR, suggesting the market price may not align with fundamental metrics relative to peer comparisons or historical averages for the sector. Investors focused on valuation should monitor whether increased attention to the company translates into operational improvements that might justify current pricing, or whether valuation compression could occur if growth expectations adjust downward. - EMR Maintained by Morgan Stanley -- Price Target Raised to $145 (gurufocus.com, 2026-10-19)
TickrTrends take: Morgan Stanley's decision to raise its price target for EMR to $145 comes against TickrTrends' current assessment that the stock is overvalued within the Industrials sector. A valuation-focused investor should monitor whether this analyst action represents meaningful fundamental improvement or primarily reflects sentiment shifts, particularly given the existing overvaluation designation. The gap between analyst price targets and TickrTrends' valuation view warrants careful examination of the underlying metrics driving the divergence. - EMR Maintained by Mizuho -- Price Target Raised to $180 (gurufocus.com, 2026-10-15)
TickrTrends take: Mizuho's raised price target to $180 reflects analyst confidence in EMR's fundamentals, though TickrTrends currently derives an overvalued assessment for the Industrials sector company. A valuation-focused reader should monitor whether the stock's trading level approaches or exceeds this new price target, as this could reinforce the overvalued positioning or signal a reassessment of fundamental value. The maintenance rating alongside the target increase suggests analysts see value preservation rather than dramatic upside, which warrants attention to how current market pricing compares to both Mizuho's target and TickrTrends' valuation metrics.
More EMR news
- Emerson Electric Co. (EMR) Is a Trending Stock: Facts to Know Before Betting on It (zacks.com, 2026-10-09)
- Investors Heavily Search Emerson Electric Co. (EMR): Here is What You Need to Know (zacks.com, 2026-09-28)
- EMR Maintained by TD Cowen -- Price Target Raised to $170 (gurufocus.com, 2026-09-25)
What people are saying
Follow the EMR conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — EMR's valuation verdict shifted from Fairly valued to Overvalued this week according to TickrTrends' derived indicators. This represents a significant change in how the Industrials sector company is being assessed relative to its fundamental metrics.
- 2026-10-06 — TickrTrends' derived indicators for EMR shifted this week as the valuation verdict moved from Overvalued to Fairly valued. This change reflects a reassessment of the company's valuation metrics within the Industrials sector. The stock is now assessed as appropriately priced relative to its fundamentals.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is EMR stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), EMR is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is EMR's TickrTrends verdict?
EMR's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does EMR compare to other Industrials stocks?
EMR ranks #74 of 106 Industrials stocks in TickrTrends' coverage by discount to fair value.
Is EMR overbought or oversold?
EMR's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does EMR pay a dividend?
Yes. EMR paid $2.22 per share over the last twelve months (4 payments), a 1.37% yield on TickrTrends' last price, and has raised the annual total for 18 consecutive years. The last ex-dividend date was 2026-08-14.
When does EMR report earnings next?
EMR's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does EMR usually beat earnings estimates?
Over its last 8 reported quarters EMR beat the consensus estimate 7 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about EMR?
Of 30 analysts covering EMR, 20 rate it a buy, 8 a hold and 2 a sell - buy-leaning, with a consensus price target of $174 (+7.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Industrials
Head-to-head comparisons
EMR vs BLDR · EMR vs CMI · EMR vs CSX · EMR vs GEV · EMR vs GWW